UNITY Biotechnology Reports Granting of New Employment Inducement Award Jan 7, 2025 04:10PM
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates Nov 4, 2024 04:30PM
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates Aug 6, 2024 04:30PM
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates May 14, 2024 05:00PM
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates Apr 15, 2024 07:00AM
View Older Stories

Feb 6, 2024 08:00AM New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
Dec 12, 2023 08:00AM UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
Nov 13, 2023 04:05PM UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
Nov 10, 2023 08:01AM UNITY Biotechnology (UBX) Announces Exercise of Warrants for $4.38M in Proceeds
Nov 10, 2023 08:00AM UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
Sep 27, 2023 07:00AM UNITY Biotechnology (UBX) Reports 48-Week Results from Phase 2 ENVISION Study of UBX1325
Sep 27, 2023 07:00AM UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Aug 8, 2023 04:05PM UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
Jun 21, 2023 07:00AM UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
May 9, 2023 04:05PM UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
Apr 24, 2023 07:04AM UNITY Biotechnology (UBX) Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325
Apr 24, 2023 07:00AM UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
Apr 23, 2023 06:00PM UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Mar 27, 2023 07:32AM UNITY Biotechnology (UBX) Reports Results from Phase 2 ENVISION Study of UBX1325
Mar 27, 2023 07:30AM UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Mar 15, 2023 04:05PM UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Feb 28, 2023 04:05PM UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
Feb 15, 2023 08:00AM UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
Feb 9, 2023 08:00AM UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
Jan 18, 2023 08:00AM UNITY Biotechnology Reports Granting of New Employment Inducement Award
Nov 8, 2022 04:10PM UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
Nov 1, 2022 07:03AM UNITY Biotechnology (UBX) Reports Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325
Nov 1, 2022 07:00AM UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
Oct 31, 2022 06:11PM UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Oct 11, 2022 08:00AM UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
Oct 6, 2022 08:00AM UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye
Sep 19, 2022 08:00AM UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration
Aug 31, 2022 08:00AM UNITY Biotechnology to Participate in Upcoming Investor Conferences
Aug 12, 2022 07:05AM UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates
Aug 12, 2022 07:00AM UNITY Biotechnology (UBX) Reports Positive Data in Phase 2 BEHOLD Study of UBX1325
Aug 12, 2022 07:00AM UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
Aug 11, 2022 05:45PM UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
Jul 12, 2022 04:00PM UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
Jun 29, 2022 08:00AM UNITY Biotechnology Reports Granting of New Employment Inducement Award
May 26, 2022 08:00AM UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors
May 25, 2022 08:00AM UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
May 10, 2022 04:00PM UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 5, 2022 08:00AM UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases
Apr 21, 2022 08:00AM UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting
Apr 19, 2022 08:00AM UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration
Apr 12, 2022 08:00AM UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema
Mar 15, 2022 08:00AM UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Mar 1, 2022 08:00AM UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference
Feb 14, 2022 08:00AM UNITY Biotechnology (UBX) Reports Additional Data from Phase 1 Study of UBX1325
Feb 14, 2022 08:00AM UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
Feb 3, 2022 04:04PM UNITY Biotechnology (UBX) Restructures to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
Feb 3, 2022 04:01PM UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
Feb 2, 2022 08:00AM UNITY Biotechnology Reports Granting of New Employment Inducement Award
Jan 4, 2022 08:00AM UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022
Dec 22, 2021 08:00AM UNITY Biotechnology Reports Granting of New Employment Inducement Award
View Older Stories